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Promoter-proximal pausing by initiated RNA poly-
merase II (Pol II) and regulated release of paused
polymerase into productive elongation has emerged
as a major mechanism of transcription activation.
Reactivation of paused Pol II correlates with recruit-
ment of super-elongation complexes (SECs) contain-
ing ELL/EAF family members, P-TEFb, and other
proteins, but the mechanism of their recruitment is
an unanswered question. Here, we present evidence
for a role of human Mediator subunit MED26 in this
process. We identify in the conserved N-terminal
domain of MED26 overlapping docking sites for
SEC and a second ELL/EAF-containing complex, as
well as general initiation factor TFIID. In addition,
we present evidence consistent with the model that
MED26 can function as a molecular switch that inter-
acts first with TFIID in the Pol II initiation complex and
then exchanges TFIID for complexes containing ELL/
EAF and P-TEFb to facilitate transition of Pol II into
the elongation stage of transcription.
INTRODUCTION
Messenger RNA synthesis begins with recruitment of RNA poly-
merase II (Pol II) and other components of the transcription appa-
ratus to the promoter to form a preinitiation complex, followed by
ATP-dependent unwinding of the DNA and transcription initia-
tion. Following initiation, Pol II moves away from the promoter,
ultimately leading to establishment of a productive elongation
complex. Although for many years most research focused on
mechanisms that control the preinitiation and initiation stages
of transcription, transcription of many genes is also regulated
during transcript elongation.
Early studies showed that transcription of genes including the
human c-myc oncogene, theDrosophila heat shock gene hsp70,92 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.and the integrated HIV-1 provirus is regulated by promoter-
proximal pausing, in which Pol II initiates transcription but
pauses or arrests downstream of the transcription start site
(Saunders et al., 2006). Release from the pause is a rate-limiting
step that can be regulated by DNA-binding transcription factors
or, in the case of HIV transcription, by the viral RNA-binding
transactivator Tat. Recently, genome-wide studies demon-
strated the presence of promoter-proximally paused Pol II near
the 50 ends of a large fraction of genes, suggesting that regulated
promoter-proximal pausing and release are general features of
Pol II elongation (Guenther et al., 2007; Kininis et al., 2009;
Muse et al., 2007; Nechaev et al., 2010; Rahl et al., 2010; Zeitlin-
ger et al., 2007).
The duration of pausing or arrest during early elongation can
be controlled by multiple transcription elongation factors that
influence the elongation competence of Pol II. DRB sensitivity-
inducing factor (DSIF) and negative elongation factor (NELF)
function together to induce pausing (Wada et al., 1998; Yamagu-
chi et al., 1999). Release of paused Pol II in turn depends on
phosphorylation of the Pol II CTD, SPT5, and perhaps other
factors by positive transcription elongation factor b (P-TEFb;
composed of the cyclin-dependent kinase CDK9 and CYCLIN
T1/T2) (Lis et al., 2000; Marshall et al., 1996; Peterlin and Price,
2006; Wei et al., 1998). Also implicated in this process are addi-
tional transcription elongation factors, including members of the
eleven-nineteen lysine-rich in leukemia (ELL) family and their
binding partners ELL-associated factors (EAFs) 1 and 2, which
together act directly to increase the rate of elongation by Pol II
in vitro and regulate expression of hsp70, HIV-1, and other genes
in cells (Byun et al., 2009; Kong et al., 2005; Lin et al., 2010;
Shilatifard et al., 1996; Smith et al., 2008). Evidence suggests
that these factors contribute not only to release of paused Pol
II but also to subsequent events occurring during transcription
elongation, including cotranscriptional RNA processing (Martin-
cic et al., 2009; Ni et al., 2004).
P-TEFb and ELL/EAF family members function as compo-
nents of larger ‘‘super-elongation complexes’’ or SECs that
contain the additional coregulators AFF4, AFF1, ENL, and AF9
(He et al., 2010; Lin et al., 2010; Sobhian et al., 2010; Yokoyama
et al., 2010). In HIV-1-infected cells, Tat activates HIV-1 tran-
scription by recruiting P-TEFb, ELL/EAF, and SEC family
members through interactions with the TAR sequence in the 50
end of the nascent HIV-1 transcript (He et al., 2010; Peterlin
and Price, 2006; Sobhian et al., 2010); however, mechanisms
responsible for bringing these factors to host genes in uninfected
cells remain poorly defined.
Mediator is an evolutionarily conserved coregulatory complex
that was first identified in yeast (Kim et al., 1994; Koleske and
Young, 1994). In metazoa, Mediator is composed of some 30
distinct subunits (Sato et al., 2004). Mediator exists in multiple,
functionally distinct forms that share a common core of subunits
and can be distinguished by the presence or absence of a kinase
module composed of CYCLIN C and isoforms of MED12,
MED13, and CDK8. Kinase module has been implicated in
both transcriptional repression and activation (Taatjes, 2010).
In metazoa a subset of Mediator contains an additional
subunit, MED26. MED26-containing Mediator copurifies with
only a small amount of kinase module, but near-stoichiometric
Pol II (Mittler et al., 2001; Sato et al., 2004; Taatjes et al.,
2002). MED26-containing Mediator appears to play a key role
in transcriptional activation (Mo et al., 2004; Na¨a¨r et al., 2002;
Ryu et al., 1999); however, to our knowledge, the mechanism(s)
by which MED26 contributes to this process is not known. Here,
we present evidence supporting the model that MED26 func-
tions in part by recruiting ELL/EAF- and P-TEFb-containing
complexes, including the SEC, to a subset of human genes.
We show that the human Mediator complex can recruit ELL/
EAF- and P-TEFb- containing complexes to promoters via a
direct interaction with the N-terminal domain (NTD) of MED26.
The MED26 NTD also binds TFIID, and TFIID and elongation
complexes interact with MED26 through overlapping binding
sites. In addition we show the following: (1) in cells wild-type
MED26, but not a MED26 mutant that prevents binding of Medi-
ator to elongation factors, regulates transcription of c-myc and
other genes; and (2) MED26 knockdown interferes with elonga-
tion factor recruitment. We propose that the MED26 NTD may
function as a molecular switch that contributes to the transition
of Pol II into productive elongation.
RESULTS
Enrichment of Elongation Factors and TFIID in Mediator
with MED26
As part of a MudPIT-based proteomic analysis of the human
Mediator complex, we generated human cell lines expressing
Mediator subunits with FLAG epitope tags, immunopurified
(IPed) FLAG-Mediator subunits and their associated proteins,
and identified proteins in anti-FLAG eluates by MudPIT mass
spectrometry. In MudPIT datasets the number of spectra corre-
sponding to peptides from a particular protein correlates with the
protein’s abundance and length. The relative amount of a partic-
ular protein in a sample can be estimated from a normalized
spectral abundance factor, or NSAF (Zhang et al., 2010).
Proteomic analysis previously allowed us to define a complete
set of humanMediator subunits (Sato et al., 2004). In-depth anal-
ysis of our MudPIT datasets revealed that additional proteins
with roles in transcription were consistently enriched in FLAG-MED26 Mediator preparations, relative to Mediator purified
through FLAG-MED19 (Figure 1A, and see Table S1 available on-
line) or other core Mediator subunits (data not shown). Among
these were initiation factor TFIID and transcription elongation
factors including ELL and EAF family members, P-TEFb
(CDK9, CYCLIN T1/T2), and MLL translocation partners AFF1,
AFF4, AF9, and ENL, all of which are components of the SEC
(He et al., 2010; Lin et al., 2010; Sobhian et al., 2010). Also
enriched were two previously uncharacterized proteins,
KIAA0947 and NARG2. The NSAF values of these proteins
were5%–20%of the average NSAF of coreMediator subunits,
suggesting that they bind only a fraction of Mediator in solution.
Docking Sites for TFIID and Elongation Factors
in the MED26 NTD
TFIID, SEC components, and KIAA0947 and NARG2 could
be enriched in FLAG-MED26 Mediator because they bind
directly to MED26 or MED26-associated Mediator. Alternatively,
because ELL/EAF can interact stably with Pol II in vitro (Banks
et al., 2007; Shilatifard et al., 1997), and MED26-containing
Mediator is enriched in Pol II, some or all of these proteins might
be associated with Pol II rather than Mediator or MED26.
To begin to address these possibilities, we asked whether the
same or distinct MED26 regions are necessary for interaction
with Mediator and Pol II and with TFIID, SEC components, and
KIAA0947 and NARG2. The most highly conserved region of
MED26 is its NTD, which is similar to the NTDs of the elongation
factors TFIIS and ELONGIN A and, based on anNMR structure of
the TFIIS NTD, can be modeled as a globular domain composed
of a four-helix bundle (Booth et al., 2000). In the MED26 C
terminus are approximately 10 amino acids that are conserved
from insects to mammals, whereas a more extended C-terminal
region of 100 amino acids is conserved in vertebrates
(Bourbon, 2008).
We generated human cell lines stably expressing the series of
FLAG-MED26 mutants diagrammed in Figure 1B and identified
proteins associated with each by MudPIT and western blotting
(Figures 1A and 1C). The MED26 C-terminal domain (residues
421–600) is sufficient for its assembly into Mediator and interac-
tion with Pol II. The most highly conserved C-terminal amino
acids are critical for these interactions because deletion of the
last eight amino acids from the MED26 C terminus disrupted
MED26 binding to Mediator and Pol II. Whether MED26 makes
direct contacts with Pol II and/or binds Pol II indirectly due to
preferential association with a form of Mediator that binds Pol
II is unclear; however, we believe that the latter possibility is
more likely because we have not detected binding of purified
Pol II to free MED26 in vitro (data not shown). Neither ELL nor
EAF family members copurified with Pol II bound to Mediator
containing MED26 lacking the NTD (Figures 1A and 1C, lanes 9
and 10), suggesting that the ELL/EAF-binding site on Pol II is
blocked when Pol II is bound to Mediator.
The MED26 NTD does not bind Mediator or Pol II. However, it
does copurify with TFIID, P-TEFb subunits, ELL and EAF family
members, other SEC components, and NARG2 and KIAA0947
(Figures 1A and 1C, lanes 6–10). Binding of these proteins is
specific for the MED26 NTD because they do not copurify with
the TFIIS- or ELONGIN A-NTDs (Figure 1D). Thus, the conservedCell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc. 93
Figure 1. Association of MED26 NTD with Transcription Elongation Factors, MLL Fusion Partners, and TFIID
(A) MudPIT of MED26-associated proteins. See also Table S1.
(B) Schematic of wild-type and mutant MED26 proteins.
(C) Western blot of FLAG-IPed complexes from HeLa cells expressing wild-type and mutant MED26 (lanes 2–5 and 7–10) and of rat liver Pol II (lane 1) (Serizawa
et al., 1992). Lanes 1–3, and 4 and 5, respectively, are from different blots.
(D) Proteins copurifying with FLAG-MED26 NTD, TFIIS NTD, or ELONGIN A NTD, analyzed by western blotting. WT, wild-type. Here and in subsequent figures, IP
and input (3% of total) were analyzed on different blots; hence, it is not possible to make quantitative comparisons between IP and input samples.MED26 N- and C-terminal regions are functional domains that
support interactions with TFIID and transcription elongation
factors and with Mediator and Pol II, respectively. Although we94 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.did not detect TFIID in association with MED26 mutants that
lack the NTD in our MudPIT analyses, we detected small
amounts of TFIID subunit TBP in association with these mutants
Figure 2. ELL/EAF-Containing Complexes Bind the MED26 NTD
(A) MudPIT of proteins bound to SEC components, NARG2, and KIAA0947.
(B) Western blotting of proteins associated with FLAG-tagged NARG2, KIAA0947, and AF9.
(C) Binding of NARG2 and KIAA0947 to ELL/EAF1. FLAG-IPed complexes from baculovirus-infected insect cells expressing the indicated proteins were analyzed
by western blotting. Asterisk indicates IgH.
(D) Binding of EAF1 to the MED26 NTD. Western blotting of FLAG-IPed complexes or lysates (Input) from baculovirus-infected insect cells, using anti-FLAG (M2)
antibodies and Alexa Fluor 680-labeled anti-mouse IgG (light chain-specific) (red) or rabbit anti-cMyc antibodies and IR Dye 800-labeled goat anti-rabbit IgG
(green).by western blotting (Figure 1C), perhaps due to interactions
between TBP and other Mediator subunits (Cai et al., 2010;
Larivie´re et al., 2006). However, we cannot rule out the possibility
that the MED26 C terminus can also bind weakly to TFIID.
ELL and EAF Are Components of at Least Two MED26
NTD-Associated Complexes
To define the complexes that interact withMED26, we generated
cell lines stably expressing individual FLAG-tagged SEC compo-
nents, NARG2, full-length KIAA0947, or KIAA0947 deletion
mutants. Analysis of proteins copurifying with each protein
argues that the MED26 NTD binds at least two types of
complexes that share ELL and EAF family members. The first
corresponds to the SEC and includes P-TEFb, AFF4 and/or
AFF1, and AF9 and/or ENL (Figures 2A and 2B, lane 4), and
the second lacks SEC components but includes KIAA0947 andNARG2 (Figures 2A and 2B, lanes 2 and 3). We detect only small
amounts of Mediator subunits by MudPIT in FLAG immunopre-
cipitates (IPs) from cells expressing SEC subunits, most notably
FLAG-AFF4 (data not shown), suggesting that only a small frac-
tion of the SEC is stably associated with Mediator. Confirming
the interaction of ELL/EAF1 with KIAA0947 and NARG2, re-
combinant ELL, EAF1, and KIAA0947 specifically co-IPed with
FLAG-NARG2 when the four proteins were coexpressed in
insect cells. The function of this novel complex will be the subject
of a future study.
EAF Proteins Bind the MED26 NTD
Having observed that ELL and EAF family members are shared
by at least two complexes that bind the MED26 NTD, we spec-
ulated that members of one or both families might directly
interact with the MED26 NTD. As shown in Figure 2D, EAF1Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc. 95
Figure 3. The MED26 NTD Is Needed for
Mediator-Dependent Recruitment of ELL/
EAF but Not TFIID to Promoters
(A) Schematic of immobilized template assay.
(B) MED26 NTD is dispensable for Mediator-
dependent recruitment of TFIID to a promoter.
Assays contained GAL4x5-MLT template and
GAL4-VP16, TFIID, and Mediator (Med) with
MED26 or MED26DNTD as indicated.
(C) Mediator-dependent recruitment of ELL/EAF1
to GAL4- (lanes 1–3) or HNF4a-responsive pro-
moters. Med(F-MED26 wt), MED26-Mediator.
(D)MED26DNTD-Mediator (Med[F-MED26DNTD])
does not recruit EAF1 to a promoter.
(E) Free MED26 is not sufficient for EAF1 recruit-
ment. In lanes 1–4, assays contained either free
full-length MED26 or MED26-Mediator. Lanes 5–8
show amounts of free MED26 and MED26-Medi-
ator in binding assays.
(F) Free MED26 NTD blocks Mediator-dependent
EAF1 recruitment. Assays were performed with
MED26-Mediator, with or without free MED26
NTD (His-MED26-NTD).bound the FLAG-MED26 NTD when the two proteins were coex-
pressed in insect cells in the absence of ELL; EAF2 also bound
the MED26 NTD in the absence of ELL (data not shown). In
contrast, ELL bound the MED26 NTD only in the presence of
an EAF family member. These findings suggest that EAF proteins
function as adaptor molecules that link the MED26 NTD to ELL/
EAF-containing complexes.
A Role for the MED26 NTD in Mediator-Dependent
Recruitment of Transcription Elongation Factors to
Promoters In Vitro
Our observation that the MED26 NTD directly binds both TFIID
and ELL/EAF-containing complexes suggested that MED2696 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.might contribute to transcriptional regula-
tion at least in part by helping to recruit
them to the genes they regulate. Carey
and coworkers (Johnson et al., 2002)
showed that Mediator enhances recruit-
ment of TFIID to a promoter bound by
a DNA-binding transactivator, GAL4-
VP16. To ask whether the MED26 NTD
is responsible for this activity of Medi-
ator, we employed similar immobilized
template assays (Figure 3A), using Medi-
ator complexes purified from cells ex-
pressing wild-type FLAG- MED26 or
MED26 that lacks the NTD but includes
residues 421–600 (MED26 DNTD). Both
MED26- and MED26 DNTD-containing
Mediator enhanced GAL4-VP16-depen-
dent binding of TFIID to an immobilized
promoter (Figure 3B), arguing that the
MED26 NTD is dispensable for TFIID
recruitment in this assay and that addi-tional contact(s) between Mediator and TFIID is responsible for
this activity.
We next tested the ability of Mediator to recruit EAF-contain-
ing complexes to promoters in the presence of either GAL4-
VP16 or the DNA-binding transactivator HNF4a. As shown in
Figures 3C and 3D, the ELL/EAF1 complex or EAF1 alone was
recruited to promoters containing GAL4- or HNF4a-responsive
elements in the presence of their cognate activator only when
binding reactions included wild-type Mediator. However, EAF1
was not recruited to either promoter in binding reactions contain-
ing MED26 DNTD-Mediator (Figure 3D).
To exclude the possibility that free MED26 protein in Mediator
preparations is responsible for EAF1 recruitment, we compared
the ability of free MED26 and FLAG-MED26-IPed Mediator to
recruit EAF1 to an immobilized promoter. Unlike Mediator-asso-
ciated MED26, free MED26 was not recruited by HNF4a to the
immobilized template and, accordingly, did not recruit EAF1
(Figure 3E). Furthermore, excess free MED26 NTD (residues
1–113) competes withMediator for EAF1 recruitment (Figure 3F).
Thus, Mediator can recruit EAF1 or EAF1-associated complexes
to immobilized promoters via direct interaction of the MED26
NTD with EAF1.
Elongation Factors and TFIID Bind to Overlapping
Surfaces of the MED26 NTD
As described above, the MED26 NTD is closely related in
sequence to the TFIIS NTD and, based on an NMR structure of
the TFIIS NTD, has been modeled as a four-helix bundle (Booth
et al., 2000). To explore whether elongation factors and TFIID
bind to distinct or overlapping surfaces of the MED26 NTD, we
generated a series of MED26 NTDmutants in which various pre-
dicted surface residues were changed to alanine and asked
whether we could identify mutations that differentially affect
MED26 NTD interactions with ELL/EAF-containing complexes
and with TFIID.
We observed that a GAL4-MED26 NTD fusion protein acts as
a strong activator of a luciferase reporter driven by five GAL4
responsive elements upstream of the AdML promoter in tran-
sient transfection assays (Figure S1A). GAL4-MED26 NTD with
alanines in place of predicted surface residues R61 and K62 or
K74 and K75 were expressed well but failed to activate the lucif-
erase reporter, whereas GAL4-MED26 NTD D13A was as active
as the wild-type GAL4-MED26 NTD. As shown in Figure S1B,
GAL4-MED26 NTD and GAL4-MED26 NTD(D13A) could both
recruit TFIID and EAF1 to immobilized DNA, whereas GAL4-
MED26 NTD(R61A,K62A) and GAL4-MED26 NTD(K74A,K75A)
could not. These residues are also critical for MED26 NTD inter-
actions with both elongation factors and TFIID in cells because
EAF1, ELL, CDK9, CYCLIN T1/T2, or TFIID subunits were not
detected by western blotting in FLAG-IPs from cells stably
expressing FLAG-MED26 NTD(R61A,K62A) or FLAG-MED26
NTD(K74A,K75A) (Figure 4A).
We next tested the ability of FLAG-MED26(R61A,K62A) to
assemble into Mediator and to interact with elongation factors
and TFIID when expressed in human cells. As expected,
both wild-type and mutant MED26 assembled into Mediator,
and Mediator containing the MED26 mutant failed to bind to
elongation factors (Figure 4B). In addition, Mediator containing
MED26(R61A,K62A) could not recruit EAF1 to a promoter
(Figure 4C). Finally, Mediator containing MED26(R61A,K62A)
could still interact with TFIID subunits (Figure 4B), consistent
with our evidence that deletion of the MED26 NTD does
not interfere with Mediator’s ability to enhance recruitment of
TFIID to a promoter in vitro (Figure 3B). We note that there
was a modest decrease in the amount of TBP and TAF6 that
co-IPed with Mediator purified from cells expressing FLAG-
MED26(R61A,K62A); however, it is not clear whether this re-
flects a small decrease in the affinity of the mutant Mediator
for TFIID or a decrease in expression of TFIID subunit(s) needed
for the interaction because TAF6 expression was decreased in
these cells.Taken together, these observations argue that ELL/EAF-con-
taining complexes and TFIID bind to the same or overlapping
surfaces of the MED26 NTD, even though interactions of TFIID
with surface(s) outside of this domain are most important for its
interaction with Mediator. In addition, they provide further
support for the idea that EAF family proteins function as adapters
that link ELL-containing complexes to Mediator via the MED26
NTD becauseMED26 double-point mutations that block interac-
tions with EAF1 in vitro also interfere with binding of the MED26
NTD or of intact Mediator to subunits of ELL/EAF-containing
complexes in cells.
These observations suggested that Mediator might not be
able to bind simultaneously to EAF1 and TFIID. Consistent
with this possibility, EAF1 recruitment to an activator-bound
promoter was substantially decreased when binding reactions
contained TFIID (Figure 4D), raising the possibility that prior to
initiation and/or the receipt of an appropriate signal, the
MED26 NTD might be masked by interaction with TFIID and
only become available to recruit ELL/EAF-containing complexes
upon release of this interaction.
MED26 Regulates Cell Proliferation and Gene
Expression
To study MED26 function in cells, we generated stable human
293T embryonic kidney cell lines expressing nontargeting or
one of three different doxycycline (Dox)-inducible short hairpin
RNAs (shRNAs) targeting the 30UTR of endogenous med26.
Dox treatment silenced MED26 protein expression in cell lines
expressing each of the Dox-inducible MED26 shRNAs (Fig-
ure 5A). Induction of any of the three MED26 shRNAs reduced
cell proliferation, whereas nontargeting shRNA had no effect
(Figures 5B and 5C). Proliferation of mouse ES cells was also
inhibited by transfection ofmed26 siRNAs, but not nontargeting
siRNA or med6, cdk8, or nontargeting siRNAs (Figures S2A
and S2B).
To identify MED26 target genes, we used Affymetrix expres-
sion arrays to analyzemRNA expression in 293T cells fromwhich
MED26 had been depleted by transient transfection of one of
three different siRNAs (Figure 5D). Of the approximately 14,550
well-characterized genes on the array, more than 10% were
significantly affected (adjusted p value %0.05) after MED26
knockdown by all 3 siRNAs. Interestingly, among the genes
most negatively regulated by MED26 depletion were c-myc
(myc), hsp70 (hspa1a), and snail2 (snai2) (Table S2). As noted
earlier, c-myc and hsp70 were among the first examples of
genes shown to be regulated during the transition from early
elongation to productive elongation (Saunders et al., 2006).
In addition, results of a recent genome-wide analysis provide
evidence that Pol II is enriched at the 50 end of the snail2 gene
in mouse ES cells (Rahl et al., 2010), and the snail2 ortholog
snail is one of many developmentally regulated genes controlled
by promoter-proximal pausing in Drosophila (Zeitlinger et al.,
2007).
Quantitative RT-PCR analysis confirmed that steady-state
expression of these and other genes was decreased following
transfection of all three MED26 siRNAs (Figure 5E and Fig-
ure S2C). Upon heat shock, synthesis of new Hsp70 mRNA
was delayed in cells transfected with MED26 siRNA (Figure 5F),Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc. 97
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Figure 4. MED26 NTD Mutants Fail to Bind ELL/EAF-Containing Complexes or TFIID
(A) Western blots of FLAG IPs or lysates (Input) from cells stably expressing the indicated FLAG-MED26 NTD proteins. Data are from the same experiment in
Figure 1D. Negative and positive controls in the first two lanes of each panel are repeated from Figure 1D.
(B) Defective binding of MED26(R61A,K62A)-Mediator to elongation factors. FLAG IPs from cells stably expressing the indicated FLAG-MED26 proteins analyzed
by silver staining (Ag stain) or western blotting (WB).
(C) MED26(R61A,K62A)-Mediator fails to recruit EAF1 to a promoter. Assays contained template, HNF4a, EAF1, and wild-type or MED26(R61A,K62A)-Mediator.
(D) TFIID blocks Mediator-dependent recruitment of EAF1 to a promoter. Assays contained template, HNF4a, EAF1, TFIID, and Mediator.
See also Figure S1.indicating that MED26 regulates not only steady-state but also
newly induced gene expression.
Effect of MED26 Depletion on SEC Recruitment and Pol
II CTD Phosphorylation at the c-myc and hsp70 Genes
To begin to investigate potential roles of MED26 in SEC recruit-
ment in cells, we focused on two examples: steady-state expres-
sion of the c-myc gene and heat shock-induced activation of the
hsp70 gene. Endogenous MED26, P-TEFb kinase CDK9, and
SEC component AFF4, as well as several exogenously ex-
pressed SEC components (FLAG-ELL, AFF1, and AF9) (Figures
6A and 6B, and Figure S3A), are detected by chromatin immuno-
precipitation (ChIP) at the c-myc gene in human cells. These98 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.observations suggest that the SEC contributes to c-myc gene
regulation and are consistent with previous evidence that
P-TEFb regulates c-myc expression (Glover-Cutter et al., 2009;
Montanuy et al., 2008). MED26, like AFF4, ELL, AFF1, and
AF9, is detected by ChIP throughout the body of the c-myc
gene in these cells, even though TBP occupancy is limited to
the promoter region as expected (Figure S3A).
Upon siRNA-mediated depletion of MED26, we observed little
change in the amount of total Pol II (detected using an antibody
that recognizes an epitope in the N terminus of RPB1) or TFIID
subunit TBP at the c-myc promoter region. About 2 kb down-
stream from the transcription start site, Pol II occupancy was
decreased by about 50%, similar to the reduction in c-Myc
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Figure 5. Effect of MED26 Depletion on Cell Prolif-
eration and Gene Expression
(A) Dox-inducible shRNA-mediated silencing of endoge-
nous MED26 expression in 293T cells stably expressing
different shRNAs. Cells were incubated with or without
Dox for 48 hr, and cell lysates were analyzed by western
blotting.
(B and C) MED26 depletion decreases cell proliferation in
293T cells stably expressing Dox-inducible shRNAs. Cell
number is expressed relative to cell number at day 5 in
cultures without Dox.
(D) Western blots for endogenous MED26 or tubulin 48 hr
after transfection of nontargeting (control) or MED26
siRNAs.
(E) Effect of siRNA-mediated MED26 depletion on gene
expression.
(F) Effect of MED26 depletion on Hsp70 induction by heat
shock. Data points are the average of three independent
experiments; error bars show standard deviation.
See also Figure S2 and Table S2.mRNA after MED26 knockdown. Occupancy of SEC compo-
nents AFF4 and CDK9 at the promoter and throughout the
body of the gene (Figure 6B) was also decreased, consistent
with evidence that the MED26 NTD contributes to recruitment
of elongation factors, but not TFIID, to promoters in vitro.
Promoter escape and transcript elongation by Pol II are associ-
ated with phosphorylation of the Pol II CTD by P-TEFb and other
kinases (Bartkowiak et al., 2010; Buratowski, 2009; Kim et al.,
2002; Marshall et al., 1996). Depletion of MED26 dramatically
decreased the amount of Ser2- and Ser5-phosphorylated Pol II
throughout the c-myc gene (Figure 6B). In control experiments
we confirmed that MED26 knockdown had no significant effect
on expression of Pol II subunit RPB1 or any of the SEC compo-
nents tested (Figure 6D).CellPrior to heat shock, an initiated but paused
Pol II is present in the promoter-proximal region
of the hsp70 gene (Core and Lis, 2008). Upon
heat shock, Mediator (Park et al., 2001) and
SEC components (Lin et al., 2010; Lis et al.,
2000; Smith et al., 2008) are rapidly recruited
to the hsp70 gene, and the paused polymerase
is released into productive elongation, allowing
additional Pol II to be recruited to the gene
(Boehm et al., 2003; Lis, 1998). Similarly, we
detect Pol II and TBP at the promoter of the
hsp70 gene prior to heat shock (Figure 6C and
Figure S3B). Consistent with our observation
that there is detectable heat shock gene expres-
sion in non-heat-shocked cells, a small amount
of Pol II (Ser2- and Ser5-phosphorylated), as
well as AFF4 and CDK9, could be detected in
the body of the gene prior to heat shock (Fig-
ure 6C). Following 7.5 or 60 min of heat shock,
Mediator subunits MED26 and MED1 and SEC
components CDK9 and AFF4 were recruited
(Figures 6A and 6C, and Figure S3B). As
observed at c-myc, the ChIP signal for MED26and, to a lesser extent, MED1 extended into the body of the
hsp70 gene (Figure S3B). After 60 min of heat shock, we
observed substantial release of Pol II into the body of the gene
and recruitment of new Pol II to the promoter (Figure S3B).
To focus on the effect of MED26 depletion on early events in
heat shock gene induction, we performed ChIP using chromatin
from cells that had or had not been subjected to just 7.5 min of
heat shock. MED26 depletion had little effect on the amount of
total Pol II or of Ser2- or Ser5-phosphorylated Pol II, AFF4, or
CDK9 at the hsp70 gene in non-heat-shocked cells (Figure 6C),
consistent with the presence of only a small amount of MED26
at the hsp70 promoter before heat shock (Figure 6A). However,
after heat shock, MED26 depletion led to a significant reduction
in new Pol II recruitment to the hsp70 promoter, accompanied by146, 92–104, July 8, 2011 ª2011 Elsevier Inc. 99
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Figure 6. Effect of MED26 Depletion on Recruitment of SEC Components and Pol II CTD Phosphorylation
(A) Occupancy of MED26 on the promoter of c-myc or hsp70 gene under non-heat- or heat-shocked condition (7.5 min).
(B and C) Effect of MED26 depletion on AFF4, CDK9, and Pol II occupancy on the c-myc or hsp70 gene under steady-state or heat-shocked conditions in
HEK293T cells. Ig, IgG (TBP, Pol II, AFF4, CDK9, and Ser5p ChIPs) or IgM (Ser2p ChIP) control; Specific ab, specific antibody.
(A)–(C) ChIP/input is average from two biological replicates; error bars show data range.
(D) MED26, Pol II, and SEC components in HEK293T cells treated with nontargeting siRNA or MED26 siRNA #4.
See also Figure S3.decreased occupancy of AFF4 andCDK9 and of Ser2- and Ser5-
phosphorylated Pol II throughout the body of the hsp70 gene.
Indeed, in heat-shocked cells depleted of MED26, the amount
of total and CTD-phosphorylated Pol II, AFF4, and CDK9 in the
body of the gene remained similar to or only modestly higher
than that observed in non-heat-shocked cells (Figure 6C).
Together, these findings suggest that MED26 contributes to
Mediator activity at multiple stages of transcription. During tran-100 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.scription of c-myc at steady state, MED26 seems particularly
important for events after Pol II recruitment, including SEC
recruitment and CTD phosphorylation. However, during activa-
tion of hsp70, MED26 knockdown not only decreases SEC
recruitment, CTD phosphorylation, and release of Pol II into the
body of the gene but also leads to a significant decrease in
new Pol II recruitment to the promoter. The effect of depleting
MED26 on Pol II distribution at hsp70 is very similar to what
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Figure 7. The MED26 NTD Regulates Cell
Proliferation and Gene Expression
(A) MED26-wt (wild-type), but not MED26-mut
(R61A,K62A), rescues proliferation defect of
MED26-depleted 293T cells expressing Dox-
inducible MED26 shRNA #3 and exogenous wild-
type or mutant MED26, grown with or without Dox.
(B) Wild-type, but not MED26(R61A,K62A), res-
cues gene expression defect of MED26-depleted
cells.
(C) Effect of overexpressing MED26 or
MED26(R61A,K62A) on Pol II occupancy at c-myc
in HeLa cells stably expressingwild-type ormutant
MED26. Ig, IgG (Pol II and Ser5p ChIPs) or IgM
(Ser2p ChIP) control; Spec ab, specific antibody.
(D) Model for Mediator and MED26 NTD function
during the transition to productive elongation. In
the initiation and/or early elongation complexes,
the EAF-binding site on the MED26 NTD is
occluded by interaction with TFIID. As Pol II moves
further from the initiation site and/or upon receipt
of a suitable signal, the MED26 NTD is released
from TFIID, allowing it to recruit ELL/EAF com-
plexes. Green and red oval indicates MED26. N,
MED26 NTD. Black bars show binding sites for
MED26 NTD on TFIID and EAF family members.was observed previously by Adelman et al. (2005) in experiments
examining the effect of depleting the elongation factor TFIIS from
Drosophila S2 cells. They attributed the decrease in new Pol II
recruitment to failure of paused Pol II to move away from the
promoter and make room for new Pol IIs to become associated
with the gene; however, it seems likely that some of the effect we
observe is due to defects in Mediator-dependent recruitment of
new Pol II after MED26 knockdown.
A Role for the MED26 NTD in Regulating Cell
Proliferation and Gene Expression
To assess the potential contribution of the MED26 NTD to regu-
lation of cell proliferation and gene expression in cells, wild-Cell 146, 92type MED26 or MED26(R61A,K62A) was
stably expressed in HEK293T cell lines
expressing Dox-inducible shRNAs target-
ing MED26. Because the MED26 shRNAs
target sequences in the med26 30UTR,
exogenously expressed MED26 mRNAs,
which do not include the 30UTR, should
not be affected by the MED26 shRNA.
Even before depletion of endogenous
MED26, the proliferation rate of cells
expressing wild-type MED26 was moder-
ately higher than that of control cells
or cells expressing MED26(R61A,K62A)
(Figure 7A, left panel). After depletion
of endogenous MED26, cells expressing
wild-type MED26 grew substantially
faster than control cells or cells express-
ing MED26(R61A,K62A) (Figure 7A, right
panel). Cells expressing mutant MED26grew more slowly than control cells after shRNA induction,
suggesting that MED26(R61A,K62A) is a dominant-negative
inhibitor of MED26 function in cells when endogenous MED26
is limiting.
To investigate further the contribution of the MED26 NTD to
gene expression, we used cell lines expressing Dox-inducible
MED26 shRNAs to test the requirement for the NTD in expres-
sion of several genes that were downregulated in cells transiently
transfected with MED26 siRNAs. As a control, we also included
cyclin D2, whichwas unaffected byMED26 knockdown inmicro-
arrays. The reduction in gene expression upon induction of
MED26 shRNA in these cell lines was not as great as the reduc-
tion seen in cells transiently transfected with MED26 siRNAs,–104, July 8, 2011 ª2011 Elsevier Inc. 101
due either to less-efficient depletion of MED26 by the shRNA in
these cell lines or to leaky expression of shRNA even without
Dox induction.
The results of these experiments are consistent with a role for
the MED26 NTD in expression of each gene tested except for
the control cyclin D2 gene; however, the responses of these
genes to exogenously expressed MED26 differed (Figure 7B).
MED26 shRNA reduced expression of c-myc and slc7a11 to
a similar extent. In both cases, exogenously expressed wild-
type MED26 blocked the effect of depleting endogenous
MED26 but led to only a modest increase in gene expression
relative to control. In contrast, snail2 expression was much
higher in wild-type MED26-expressing cells than in control cells
even before induction of MED26 shRNA, suggesting that MED26
is limiting for snail2 expression in human embryonic kidney cells.
In each case, MED26(R61A,K62A) had a dominant-negative
effect because its expression led to an approximately 2-fold
decrease in mRNA levels whether or not the MED26 shRNA
was induced.
To explore further the contribution of the MED26 NTD to gene
regulation, we asked whether overexpression of wild-type
MED26 or MED26(R61A,K62A) differentially affects Pol II distri-
bution or CTD phosphorylation at the c-myc gene; these exper-
iments were performed using the same HeLa cell lines in which
we showed that both wild-type and mutant MED26 are fully
capable of assembling into Mediator. Overexpression of wild-
type but not mutant MED26 led to a small decrease in the
amount of total Pol II at the c-myc promoter and a concomitant
small increase in total Pol II further downstream, consistent with
the possibility that more Pol II is released from the promoter
region in cells overexpressing wild-type MED26 (Figure 7C). In
addition, overexpression of wild-type but not mutant MED26
increased the amount of Ser2- and Ser5-phosphorylated
Pol II at the promoter and throughout the body of the gene.
Notably, the effect of MED26 overexpression on Ser2 phos-
phorylation was more pronounced than the effect on Ser5
phosphorylation. Thus, a MED26 NTD mutation that prevents
the interaction of Mediator with transcription elongation factors
interferes with MED26 functions in cell proliferation and gene
regulation.
DISCUSSION
In this report, we show that the conserved NTD of MED26 func-
tions as a docking site on Mediator for at least two types of
complexes that contain members of the ELL/EAF family of tran-
scription elongation factors: the multimeric SECs, which also
contain P-TEFb and the MLL translocation partners AFF4,
AFF1, ENL, and AF9, and an additional ELL/EAF-containing
complex of as yet unknown function.
In addition to ELL/EAF-containing complexes, the MED26
NTD contains a binding site for TFIID. However, consistent
with evidence that yeast Mediator, which lacks MED26, binds
TBP through contacts with MED8 and other subunits in the
head module (Cai et al., 2010; Larivie´re et al., 2006), mutation
of the MED26 NTD does not affect Mediator’s ability to enhance
binding of TFIID to a promoter, arguing that the MED26 NTD
is not solely responsible for Mediator’s interaction with TFIID.102 Cell 146, 92–104, July 8, 2011 ª2011 Elsevier Inc.Together with our observation that prior binding of Mediator to
TFIID at a promoter prevents Mediator from recruiting Pol II
elongation factors via the MED26 NTD, this finding raises the
possibility that the MED26 NTD is a molecular switch that
interacts first with the Pol II initiation complex through direct
interactions with TFIID and then exchanges TFIID for Pol II
elongation factors to facilitate productive elongation and/or
other elongation-associated processes modulated by these
factors (Figure 7D). Consistent with this model, MED26 knock-
down has little or no effect on TBP occupancy at the c-myc
and hsp70 promoters.
There is precedent for the idea that Mediator has a role in
controlling events that occur during transcription elongation.
Deletion of MED23 from mouse ES cells eliminates expression
of the serum-response gene egr1 due to (1) loss of Mediator
recruitment and (2) failure to release Pol II from the promoter
region (Balamotis et al., 2009; Wang et al., 2005). In yeast, Medi-
ator subunits are detected byChIP not only at promoters but also
in the coding regions of some genes (Andrau et al., 2006; Zhu
et al., 2006). In human cells the Mediator kinase module subunit
CDK8 has been localized to coding regions of genes it activates
(Donner et al., 2007, 2010). Similarly, we show that MED26 can
be detected in the body of both the c-myc and hsp70 genes.
Thus, interactions between MED26 and the SEC might
contribute not only to SEC recruitment near the transcription
start site but also to SEC recruitment or retention throughout
elongation. Finally, several recent studies suggest a role for the
Mediator kinasemodule in recruiting P-TEFb following activation
of egr1 and other serum-response genes (Donner et al., 2010)
and the thyroid hormone receptor-activated gene dioI (Belaka-
vadi and Fondell, 2010). Although the relationship between
MED26 and kinase module in gene regulation remains to be
determined, there is little overlap between the genes most
affected by manipulating MED26 expression in our studies and
those found previously to be most affected by manipulating
CDK8 expression (Donner et al., 2007, 2010). This, together
with evidence for the existence of both free kinase module and
of forms of Mediator containing either MED26 or kinase module,
raises the possibility that MED26 and the kinase module act via
distinct mechanisms to recruit elongation factors to different
genes and/or under different conditions.
Finally, our results have implications for mechanisms under-
lying misregulation of gene expression in mixed lineage leuke-
mias caused by translocations of theMLL gene to one of a large
number of translocation partners. Among these translocation
partners are the SEC components ELL, AFF4, AFF1, AF9, and
ENL. The finding that in normal cells these proteins are found
together in the SEC, together with recent evidence that MLL
fusion proteins themselves can assemble into larger, SEC-like
complexes (Lin et al., 2010; Yokoyama et al., 2010), is consistent
with the model that inappropriate gene activation in mixed
lineage leukemias may be due to mistargeting of SEC-like
complexes by MLL fusion proteins (Lin et al., 2010; Mueller
et al., 2009; Yokoyama et al., 2010). Our demonstration that
the SEC binds Mediator through the MED26 NTD suggests
that mistargeting of the SEC by MLL fusion proteins could also
lead to inappropriate activation of some genes by recruitment
of Mediator and Pol II to aberrant chromosomal locations.
EXPERIMENTAL PROCEDURES
Cell Culture, Cell Lines
Parental HeLa S3 and Flp-In 293 cells (Invitrogen, Carlsbad, CA, USA) and their
derivatives were cultured as described (Cai et al., 2007; Sato et al., 2004).
Construction of expression plasmids and generation of cell lines are described
in Extended Experimental Procedures.
Western Blotting, Immunoprecipitation, and Affinity Purification
Antibodies used are described in Extended Experimental Procedures. Protein
complexes were purified from cell lines stably expressing FLAG-tagged
proteins using anti-FLAG (M2) agarose (Sigma) as described (Takahashi
et al., 2009).
Mass Spectrometry
Proteins were identified using MudPIT; for details see Extended Experimental
Procedures. NSAFs (Zhang et al., 2010) were used to estimate relative protein
abundance.
Immobilized Template Assays
Biotinylated DNA fragments from the plasmids pG5MLT or pREx4MLT, which
contain tandemly repeated GAL4- or HNF4a-responsive elements, respec-
tively, were generated and bound to Dynabeads (Dynal). Recruitment assays
were performed essentially as described (Takahashi et al., 2009).
Gene Expression Analysis and ChIP
Total RNA fromHEK293T cells transfected with nontargeting control orMED26
siRNAs or from cell lines stably expressing MED26 shRNAs, with or without
MED26 rescue constructs, was used to measure genome-wide gene expres-
sion with Affymetrix U133A plus 2.0 expression arrays or to measure expres-
sion of individual genes by qPCR. ChIP assays were performed with normal
IgG or the indicated antibodies, and precipitated DNA was measured by
qPCR. Primer sets, methods for gene expression and ChIP analyses, and
siRNAs and shRNAs are detailed in Extended Experimental Procedures.
ACCESSION NUMBERS
Microarray data are deposited in GEO under accession number GSE28715.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, three
figures, and two tables and can be found with this article online at doi:10.1016/
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